Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Centrum is bearish on Biocon has recommended sell
Ashwani Gujral of ashwanigujral.com recommends sel
ICICI Direct recommended hold rating on Biocon wit
Axis Direct recommended hold rating on Biocon with
According to Hemant Thukral of Aditya Birla Money,